Canada markets close in 3 hours 16 minutes

Therma Bright Inc. (THRM.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.4600+0.0050 (+1.10%)
As of 12:42PM EDT. Market open.
Full screen
Previous Close0.4550
Open0.4600
Bid0.4550 x 0
Ask0.4600 x 0
Day's Range0.4400 - 0.4850
52 Week Range0.0650 - 1.0500
Volume1,804,081
Avg. Volume924,619
Market Cap97.022M
Beta (5Y Monthly)3.47
PE Ratio (TTM)N/A
EPS (TTM)-0.0410
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Therma Bright Files Application to the OTCQB and DTC Clearing
    Newsfile

    Therma Bright Files Application to the OTCQB and DTC Clearing

    Toronto, Ontario--(Newsfile Corp. - July 29, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that it has applied for OTCQB listing and full eligibility through the Depository Trust Company (DTC), a subsidiary of the Depository Trust & Clearing Corp., which manages the electronic clearing and settlement of publicly

  • IIROC Trading Resumption - THRM
    CNW Group

    IIROC Trading Resumption - THRM

    Trading resumes in:

  • Therma Bright Awaits FDA-EUA Approval From Over 260 AcuVid(TM) Clinical Study Test Results
    Newsfile

    Therma Bright Awaits FDA-EUA Approval From Over 260 AcuVid(TM) Clinical Study Test Results

    Toronto, Ontario--(Newsfile Corp. - July 22, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to provide an update on its AcuVid™ COVID-19 Rapid Antigen Saliva Test and awaits an official response from the U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) review for its COVID-19 rapid antigen test applic